Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
06/2003
06/04/2003EP0938496B1 Heptapeptide oxytocin analogues
06/04/2003EP0917470B1 Composition containing a dried animal stomach mucosa, process for preparing said composition and use thereof
06/04/2003EP0909175B1 Non-aqueous protic peptide formulations
06/04/2003EP0904098B1 Compositions comprising antifungal agent and acetate buffer
06/04/2003EP0885010B1 Intercellular adhesion molecule powder formulation
06/04/2003EP0859838B1 Novel procollagens
06/04/2003EP0789578B1 Multicatalytic protease inhibitors
06/04/2003EP0692028B1 Pharmaceuticals based on papillomaviruses
06/04/2003EP0679189B1 Cloning of enterokinase and method of use
06/04/2003EP0670730B1 Fusion protein comprising two tumor necrosis factor receptors
06/04/2003EP0571602B1 Dimer of molecular variant of apolipoprotein and processes for the production thereof
06/04/2003CN1422334A Ecdysone receptor-based inducible gene expression system
06/04/2003CN1422333A Polypeptide inducing apoptosis
06/04/2003CN1422280A Novel collagen-like protein CLAC, Precursor thereof and genes encoding the same
06/04/2003CN1422279A Selective N-acylation of A82846 glycopeptide analogs
06/04/2003CN1422278A kahalalide F及相关化合物 kahalalide F and related compounds
06/04/2003CN1422245A Method for synthesis of N-[(S)-1-carboxybutyl]-(S)-alanine esters and use in synthesis of perindopril
06/04/2003CN1422163A Formulation solubilizing water-insoluble agents and preparation method thereof
06/04/2003CN1422160A Nasal calcitonin formulations
06/04/2003CN1422154A The treatment of respiratory diseases
06/04/2003CN1422149A Pharmaceutical compositions
06/04/2003CN1422121A Protein stabilised emulsions
06/04/2003CN1421461A Fusion protein with reinforced erythrocytin activity in vivo
06/04/2003CN1421457A New human protein with cancer cell growth inhibiting function and its coding sequence
06/04/2003CN1421456A Human apolipoprotein polypeptide and its use in resisting vascular proliferation diseases
06/04/2003CN1421246A Recombinant human insulin compound, its prepn and medicine composition containing the compound
06/04/2003CN1421245A Recombinant human interleukin-11 prepn for injection and its prepn process
06/04/2003CN1421244A Application of osteogenic growth peptide in promoting bematogenesis
06/04/2003CN1110563C Process for producing gene engineering leukocyte medicines from silkworm
06/04/2003CN1110559C Gene for regulating aureobasidin sensitivity
06/04/2003CN1110558C Novel growth/differentiation factor of the TGF-ÔÇÿbetaÔÇÖfamily
06/04/2003CN1110557C LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idio type antibody
06/04/2003CN1110556C Isolated nucleic acid molecules for coding tumor rejection antigen precursor MAGE-3 and use thereof
06/04/2003CN1110503C Isolated, truncated nucleicacid molecules of codeed GAGE tumor exclusion antigen
06/04/2003CN1110321C Enteric insulin capsule for treating diabetes
06/04/2003CN1110320C Medicine preparation containing glucokinase and its preparation method
06/04/2003CN1110319C Antineoplastic medicine and health-care food containing earthworm plasmin
06/04/2003CN1110318C Antithrombosis medicine using inactive insuline as skeleton and containing arginine-glycine-aspartic acid sequence
06/04/2003CN1110301C Therapeutic preparation for inhalation
06/03/2003US6573431 Recombinant preduodenal lipases and polypeptides derivatives produced by plants, processes for obtaining them and their uses
06/03/2003US6573368 Compositions for the treatment and diagnosis of breast cancer and methods for their use
06/03/2003US6573365 Of given amino acid sequence; Nuclear Factor of Activated T Cells (NF-AT); can use in identifying agents that modulate their activity
06/03/2003US6573364 Isolation and characterization of Hermansky Pudlak Syndrome (HPS) protein complexes and HPS protein-interacting proteins
06/03/2003US6573362 Of given amino acid sequence; binding inhibition; can use in reducing or influencing inflammations, improving wound healing, suppressing theimmune system for organ transplants, preventing metastasis of tumors and treating arteriosclerosis
06/03/2003US6573361 Antifungal proteins and methods for their use
06/03/2003US6573360 Human ABH
06/03/2003US6573282 Peripherally active anti-hyperalgesic opiates
06/03/2003US6573259 Inhibitors of interleukin-1β converting enzyme
06/03/2003US6573249 Topical wound therapeutic compositions
06/03/2003US6573244 Previns as specific inhibitors and therapeutic agents for Botulinum toxin B and Tetanus neurotoxins
06/03/2003US6573243 Pompilid wasp-derived neuropeptides
06/03/2003US6573242 Composition for activating macrophages comprising S-(2,3-dihydroxypropyl)-cysteine peptide having two fatty acids bonded as esters to dihydroxypropyl group and having specified amino acid sequence
06/03/2003US6573241 Therapeutic agent for the suppression of snoring noises
06/03/2003US6573239 Compound comprising 15 to 26-residue peptide or peptide analogue which forms amphipathic alpha-helix in presence of lipids and exhibits specified lecithin:cholesterol acyltransferase activation activity
06/03/2003US6573238 A biodegradable microparticle by forming a coating of a viscous form of a polypeptide e.g., insulin-like growth factor, with a poly(alpha-hydroxy acid), a polyhydroxybutyric acid, a polycaprolactone, a polyorthoester or a polyanhydride
06/03/2003US6573237 Soluble formulation comprising nicotinamide, hydrophobic preservative, and medically useful peptide or protein selected from follicle stimulating hormone and its variants
06/03/2003US6573100 DNA vectors without a selection marker gene
06/03/2003US6573095 Polynucleotides isolated from skin cells
06/03/2003US6573094 F-box genes and proteins
06/03/2003US6573082 Streptococcus pneumoniae antigens and vaccines
06/03/2003US6573078 Human immunodeficiency virus (HIV) protein fragments having antiviral activity; peptides derived from HIV transmembrane glycoprotein that inhibit HIV-induced cell-cell fusion; use for inhibition of enveloped viral infection
06/03/2003US6573073 Oligonucleotide regulatory sequence that increases promoter activity; vectors; gene therapy for cystic fibrosis; cystic fibrosis transmembrane conductance regulator (CFTR)
06/03/2003US6573071 Given amino acid sequence with a modification resulting in a different processing site; use in treating blood disorders
06/03/2003US6573067 Nucleic acid encoding sodium channels in dorsal root ganglia
06/03/2003US6573066 FtsH from Staphylococcus aureus
06/03/2003US6573062 Method for obtaining modulators of TNF receptor releasing enzyme
06/03/2003US6573061 Purified fragment of myosin-II, actin, and cardiac regulatory proteins, which exhibit calcium regulated myosin ATPase activity; use in high throughput drug screening for heart failure
06/03/2003US6573060 Methods and compositions for targeting DNA metabolic processes using aminoglycoside derivatives
06/03/2003US6573058 Which binds immunospecifically; encoded by a cDNA contained within a plasmid; can use to develop antiviral drugs that block entry into cells
06/03/2003US6573057 Pain therapy; modulator of gene expression
06/03/2003US6573003 Soluble recombinant fusion protein comprising a nontoxin protein sequence and portion of Clostridium difficile toxin B amino acid sequence 10; pseudomembranous enterocolitis; side effect free; low cost
06/03/2003US6572894 Biodegradable polymer
06/03/2003US6572893 Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
06/03/2003US6572866 Nerve growth factor as a vaccine adjuvant
06/03/2003US6572860 ICP27, glycoprotein B, ribonucleotide reductase, ICP4, ICP34.5, glycoprotein E or glycoprotein F and an immunomodulatory peptide which is a portion of an immunoprotein which promotes binding to a class of T cells and
06/03/2003US6572859 Hypoallergenic polypeptide consisting of an amino acid sequence of SEQ ID NO: 20 and 21; Phl p6 molecule has an N-terminal and/or C-terminal deletion which makes the molecule at least substantially lack IgE binding capacity
06/03/2003US6572857 Psoriasis; humanized sub clone of IOR T1A produced by the hybridoma deposited with ECACC, CAMR under accession number 96112640, having heavy and light chains with humanized variable regions.
06/03/2003US6572856 Classic complement pathway, C3 convertase
06/03/2003US6572855 Use of hyaluronidase in the manufacturing of a drug for the treatment of inflammation
06/03/2003US6572854 Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria
06/03/2003US6572853 Recombinant human beta interferon with enhanced solubility
06/03/2003US6572852 Genetic engineering
06/03/2003US6572851 Method for suppressing or treating drug-induced nephropathy
06/03/2003US6572605 Implantable device and use therefor
06/03/2003CA2413491A1 Treatment for ischemic stroke
06/03/2003CA2138997C Vaccine composition containing adjuvants
06/03/2003CA2108266C Convertible microemulsion formulations
06/03/2003CA2094275C Methods and compositions for the treatment of cell proliferation disorders
06/03/2003CA2076424C Phosphoinositol-glycan-peptide with insulin-like action
05/2003
05/30/2003WO2003044529A1 Modulators of lymphocyte activation, mkk3b compositions and methods of use
05/30/2003WO2003044218A1 Methods and compositions for the treatment and diagnosis of cellular proliferative disorders using 32222
05/30/2003WO2003044214A2 Methods and compositions in checkpoint signaling
05/30/2003WO2003044196A1 Postsynaptic proteins
05/30/2003WO2003044175A2 Methods and use of motoneuronotropic factors
05/30/2003WO2003044174A2 Mammary-associated serum amyloid a3 promoter sequences and uses for same
05/30/2003WO2003044173A2 Antitumor activity of bok
05/30/2003WO2003044172A2 Composition comprising and method of using angiopoietin-like protein 3 angptl3
05/30/2003WO2003044171A2 Organelle-associated proteins
05/30/2003WO2003044170A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use
05/30/2003WO2003044167A2 Antisense modulation of human fxr expression
1 ... 1835 1836 1837 1838 1839 1840 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 ... 3163